Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

As Blind Wagers Go, You Could Do Worse Than Pershing Square Tontine Holdings

By Josh Enomoto, InvestorPlace Contributor

Fundamentally, PSTH stock may be running out of merger options. But sentiment is probably strong for this blank check firm.

Intriguing Cardano Is Still Hoping for a Bitcoin Bull

By Josh Enomoto, InvestorPlace Contributor

On paper, the proof-of-stake protocol underlining Cardano should allow it to trade independently against Bitcoin but so far, that’s not really happening.

Strong Backing for OrganiGram Doesn’t Answer All Questions

By Josh Enomoto, InvestorPlace Contributor

While British American Tobacco gave OGI stock an excellent credibility boost, this alone doesn’t answer why shares were risky in the first place.

Ideanomics Has Lots of Big Plans, but Shareholders May Be Losing Interest

By Josh Enomoto, InvestorPlace Contributor

While its underlying electric vehicle business may be intriguing, the technical sentiment for IDEX stock leaves much to be desired.

Iterum Therapeutics’ Science Won’t Prevent Its Volatility

By Josh Enomoto, InvestorPlace Contributor

Fundamentally, ITRM stock is an excellent play on multi-drug resistance pathogen solutions but you must also be aware of its extreme boom-bust cycles.

Load More